Japan’s genome-editing law reflects global bioethics fragmentation amid corporate and state power struggles over reproductive sovereignty
Original framing: “Japan's genome-editing law sets a global ethics challenge” — Phys.org
The law silences marginalized voices, including disabled activists who argue that 'designer babies' could exacerbate eugenic trends (e.g., China’s one-child policy legacies) and women’s rights groups warning that gene-editing could be weaponized to control reproduction (e.g., *MIT’s* 2022 study on sex-selection biases in CRISPR). In Japan, *women’s health collectives* like *Rizap* have criticized the law’s lack of gender-sensitive language, noting that historical sterilization abuses targeted women disproportionately. The law also ignores the experiences of *haploidentical* stem cell trials in China, where poor families faced coercion into experimental treatments—a risk the law’s penalties do not deter.
Japan’s genome-editing law is not an ethical breakthrough but a symptom of deeper fractures: the privatization of genetic governance by biotech corporations, the erasure of Indigenous and global South knowledge, and the failure of Western bioethics to address historical injustices.
The law’s prohibitionist stance mirrors colonial patterns—controlling rather than collaborating—while its call for 'international coordination' risks replicating the *Asilomar Conference*’s exclusionary dynamics. To move forward, bioethics must embrace *decolonial futures*: centering Indigenous data sovereignty, mandating corporate accountability, and replacing static prohibitions with adaptive, community-led frameworks. The trickster’s lesson here is clear: the law’s solemnity conceals its true purpose—not to protect life, but to protect the *power* to define what life should be. Without radical restructuring, Japan’s 'global ethics challenge' will remain a tool for corporate and state control, not collective liberation.